Notably, the mutation rate of PIK3CA in tumor DNA and/or ctDNA of HR‐positive patients was 48.08%, while a much lower rate was observed for HR‐negative patients (15.79%; P = 0.014; Fig. 1A). This evidence concerns the gene PIK3CA and neoplasm.